首页> 美国卫生研究院文献>Antibiotics >Resistance Levels and Epidemiology of Non-Fermenting Gram-Negative Bacteria in Urinary Tract Infections of Inpatients and Outpatients (RENFUTI): A 10-Year Epidemiological Snapshot
【2h】

Resistance Levels and Epidemiology of Non-Fermenting Gram-Negative Bacteria in Urinary Tract Infections of Inpatients and Outpatients (RENFUTI): A 10-Year Epidemiological Snapshot

机译:住院患者和门诊患者泌尿道感染中抵抗性革兰氏阴性菌的耐药水平和流行病学(RENFUTI):十年流行病学快照

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Background: Urinary tract infections (UTIs) are one of the most common infections in the human medicine, both among outpatients and inpatients. There is an increasing appreciation for the pathogenic role of non-fermenting Gram-negative bacteria (NFGNBs) in UTIs, particularly in the presence of underlying illnesses. Methods: The study was carried out using data regarding a 10-year period (2008–2017). The antimicrobial susceptibility testing was performed using the disk diffusion method, E-tests, and broth microdilution. Results: NFGNB represented 3.46% ± 0.93% for the outpatients, while 6.43% ± 0.81% of all positive urine samples for the inpatients (p < 0.001). In both groups, Pseudomonas spp. (78.7% compared to 85.1%) and Acinetobacter spp. (19.6% compared to 10.9%), were the most prevalent. The Acinetobacter resistance levels were significantly higher in inpatients isolates (p values ranging between 0.046 and <0.001), while the differences in the resistance levels of Pseudomonas was not as pronounced. The β-lactam-resistance levels were between 15–25% and 12–28% for the Acinetobacter and Pseudomonas spp., respectively. 4.71% of Acinetobacter and 1.67% of Pseudomonas were extensively drug resistant (XDR); no colistin-resistant isolates were recovered. Conclusions: Increasing resistance levels of the Acinetobacter spp. from 2013 onward, but not in the case of the Pseudomonas spp. Although rare, the drug resistant NFGNB in UTIs present a concerning therapeutic challenge to clinicians with few therapeutic options left.
机译:背景:无论是门诊病人还是住院病人,泌尿道感染(UTIs)是人类医学中最常见的感染之一。非发酵革兰氏阴性细菌(NFGNB)在UTI中的致病作用越来越受到人们的赞赏,特别是在存在潜在疾病的情况下。方法:本研究使用十年期(2008-2017年)的数据进行。使用圆盘扩散法,E检验和肉汤微量稀释法进行了药敏试验。结果:门诊患者的NFGNB占尿液阳性样本的3.46%±0.93%,而住院患者所有阳性尿液样本的NFGNB占6.43%±0.81%(p <0.001)。在两组中,假单胞菌属。 (78.7%,而85.1%)和不动杆菌属。 (19.6%比10.9%)最为普遍。住院分离株的不动杆菌耐药水平显着较高(p值介于0.046和<0.001之间),而假单胞菌耐药水平的差异并不明显。不动杆菌和假单胞菌的β-内酰胺耐药水平分别在15–25%和12–28%之间。 4.71%的不动杆菌和1.67%的假单胞菌具有广泛耐药性(XDR);没有发现抗大肠菌素的分离株。结论:不动杆菌属的耐药水平增加。从2013年开始,但不是 Pseudomonas spp。尽管很少见,但UTI中的抗药性NFGNB却给临床医生带来了令人担忧的治疗挑战,几乎没有治疗选择。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号